528 related articles for article (PubMed ID: 28674296)
1. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
Igawa T
Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
[TBL] [Abstract][Full Text] [Related]
2. Alternative molecular formats and therapeutic applications for bispecific antibodies.
Spiess C; Zhai Q; Carter PJ
Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
Kitazawa T; Shima M
Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
[TBL] [Abstract][Full Text] [Related]
5. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
6. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
8. Engineering therapeutic bispecific antibodies using CrossMab technology.
Klein C; Schaefer W; Regula JT; Dumontet C; Brinkmann U; Bacac M; Umaña P
Methods; 2019 Feb; 154():21-31. PubMed ID: 30453028
[TBL] [Abstract][Full Text] [Related]
9. Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
Shiraiwa H; Narita A; Kamata-Sakurai M; Ishiguro T; Sano Y; Hironiwa N; Tsushima T; Segawa H; Tsunenari T; Ikeda Y; Kayukawa Y; Noguchi M; Wakabayashi T; Sakamoto A; Konishi H; Kuramochi T; Endo M; Hattori K; Nezu J; Igawa T
Methods; 2019 Feb; 154():10-20. PubMed ID: 30326272
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
11. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
12. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
13. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
Thakur A; Lum LG
Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
[TBL] [Abstract][Full Text] [Related]
14. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
[TBL] [Abstract][Full Text] [Related]
15. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
Moore GL; Bernett MJ; Rashid R; Pong EW; Nguyen DT; Jacinto J; Eivazi A; Nisthal A; Diaz JE; Chu SY; Muchhal US; Desjarlais JR
Methods; 2019 Feb; 154():38-50. PubMed ID: 30366098
[TBL] [Abstract][Full Text] [Related]
16. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.
Sampei Z; Igawa T; Soeda T; Okuyama-Nishida Y; Moriyama C; Wakabayashi T; Tanaka E; Muto A; Kojima T; Kitazawa T; Yoshihashi K; Harada A; Funaki M; Haraya K; Tachibana T; Suzuki S; Esaki K; Nabuchi Y; Hattori K
PLoS One; 2013; 8(2):e57479. PubMed ID: 23468998
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
Hönemann D; Kufer P; Rimpler MM; Chatterjee M; Friedl S; Riecher F; Bommert K; Dörken B; Bargou RC
Leukemia; 2004 Mar; 18(3):636-44. PubMed ID: 14737072
[TBL] [Abstract][Full Text] [Related]
18. A complex substitute: antibody therapy for hemophilia.
Lillicrap D
Nat Med; 2012 Oct; 18(10):1460-1. PubMed ID: 23042345
[No Abstract] [Full Text] [Related]
19. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.
Dhimolea E; Reichert JM
MAbs; 2012; 4(1):4-13. PubMed ID: 22327426
[TBL] [Abstract][Full Text] [Related]
20. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Kitazawa T; Igawa T; Sampei Z; Muto A; Kojima T; Soeda T; Yoshihashi K; Okuyama-Nishida Y; Saito H; Tsunoda H; Suzuki T; Adachi H; Miyazaki T; Ishii S; Kamata-Sakurai M; Iida T; Harada A; Esaki K; Funaki M; Moriyama C; Tanaka E; Kikuchi Y; Wakabayashi T; Wada M; Goto M; Toyoda T; Ueyama A; Suzuki S; Haraya K; Tachibana T; Kawabe Y; Shima M; Yoshioka A; Hattori K
Nat Med; 2012 Oct; 18(10):1570-4. PubMed ID: 23023498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
